SCHEMBL4746501

SCHEMBL4746501

O=C1c2c(O)c3n(c2CCN1Cc1ccccn1)CCN(Cc1ccc(F)cc1)C3=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.43
GRM2 Q14416 1/20 0.43
POLB P06746 2/20 0.43
TSHR P16473 1/20 0.43
DDB1 Q16531 1/20 0.42
CRBN Q96SW2 1/20 0.42
SCD O00767 1/20 0.41
CLPP Q16740 1/20 0.41
RIPK3 Q9Y572 1/20 0.40
LMNA P02545 5/20 0.39
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 1/20 0.39
GFER P55789 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
PKM P14618 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39
HTT P42858 3/20 0.39
HDAC1 Q13547 1/20 0.38
AKR1B1 P15121 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5126325 0.89 KCNH2 (0.47) KCNH2GRM2POLBCLPPLMNA
SCHEMBL4746542 0.88 KCNH2 (0.41) KCNH2GRM2POLBTSHRSCD
SCHEMBL4746127 0.87 KCNH2 (0.44) KCNH2GRM2POLBCLPPRIPK3
SCHEMBL4744312 0.85 KCNH2 (0.41) KCNH2GRM2POLBCLPPLMNA
SCHEMBL4748853 0.85 CLPP (0.44) KCNH2GRM2SCDCLPPLMNA
SCHEMBL4746444 0.85 CLPP (0.44) KCNH2GRM2SCDCLPPLMNA
SCHEMBL4750297 0.84 KCNH2 (0.43) KCNH2GRM2POLBCLPPLMNA
SCHEMBL4745898 0.83 KCNH2 (0.43) KCNH2GRM2POLBCLPPLMNA
SCHEMBL4743154 0.81 RAB9A (0.44) KCNH2GRM2POLBCLPPLMNA
SCHEMBL4743883 0.81 KCNH2 (0.43) KCNH2GRM2CLPPLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1677599-A4 HYDROXY PYRIDOPYRROLOPYRAZINE DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2008-10-22 EP claimed
US-7435735-B2 Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors MERCK & CO., INC. (US) 2008-10-14 US claimed
US-20070093496-A1 Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-04-26 US claimed
EP-1677599-A1 HYDROXY PYRIDOPYRROLOPYRAZINE DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-07-12 EP claimed
WO-2005041664-A1 HYDROXY PYRIDOPYRROLOPYRAZINE DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-05-12 WO claimed
US-7435735-B2 Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors MERCK & CO., INC. (US) 2008-10-14 US disclosed
US-7435735-B2 Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors MERCK & CO., INC. (US) 2008-10-14 US disclosed
US-20070093496-A1 Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-04-26 US disclosed
US-20070093496-A1 Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093496-A1 Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors DHPS, DPYD, TYMP KCNH2 1318/4885GRM2 4487/4885POLB 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.